Gene: LDLRAD3

143458
LRAD3
low density lipoprotein receptor class A domain containing 3
protein-coding
11p13
Ensembl:ENSG00000179241 MIM:617986 Vega:OTTHUMG00000166313 UniprotKB:Q86YD5
NC_000011.10
SNP Mapped
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.427e-1 (AD)  6.473e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs11033401chr11:36073797 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg15948836chr11:36114126LDLRAD33.100e-10Smoking27651444
cg15108490chr11:36177699LDLRAD35.400e-10Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
WWTR10.842
CMTM60.838
TANC10.838
IRAK40.828
NEDD40.824
KDELC20.819
DRAM10.81
MSN0.803
MYL12A0.803
CMTM30.801

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KCNB2-0.529
LRTM2-0.524
MARCH4-0.522
HAS1-0.522
KCNQ4-0.514
MYADML2-0.514
CDH22-0.504
BCL11A-0.504
FBLN7-0.503
NEUROD6-0.499

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in increased expression of LDLRAD3 mRNA"28433925
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LDLRAD3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LDLRAD3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LDLRAD3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LDLRAD3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LDLRAD3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LDLRAD3 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of LDLRAD3 mRNA19770486
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in decreased expression of LDLRAD3 mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of LDLRAD3 mRNA19770486|2071347
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of LDLRAD3 mRNA"19150397
D004958EstradiolEstradiol results in increased expression of LDLRAD3 mRNA23019147
C006780bisphenol A"[Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in increased expression of LDLRAD3 mRNA"28433925
D003033Coal TarCoal Tar results in decreased expression of LDLRAD3 mRNA27858113
D002945CisplatinCisplatin results in decreased expression of LDLRAD3 mRNA27594783
D004041Dietary Fats[Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of LDLRAD3 mRNA28433925
D004041Dietary FatsDietary Fats results in increased expression of LDLRAD3 mRNA18042831
D019422Dietary Sucrose[Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of LDLRAD3 mRNA28433925
D004051Diethylhexyl Phthalate"[Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in increased expression of LDLRAD3 mRNA"28433925
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LDLRAD3 mRNA22079256
C546771gardiquimodgardiquimod results in increased expression of LDLRAD3 mRNA28003376
C546771gardiquimodProtein Kinase Inhibitors inhibits the reaction [gardiquimod results in increased expression of LDLRAD3 mRNA]28003376
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LDLRAD3 mRNA25613284
C008261lead acetatelead acetate results in increased expression of LDLRAD3 mRNA21829687
D058185Magnetite Nanoparticles[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of LDLRAD3 mRNA26378955
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of LDLRAD3 mRNA"25554681
D009538NicotineNicotine results in increased splicing of LDLRAD3 mRNA alternative form23825647
D010100OxygenOxygen deficiency results in increased expression of LDLRAD3 mRNA24205000
D000073878Palm OilPalm Oil results in increased expression of LDLRAD3 mRNA18042831
D010634PhenobarbitalPhenobarbital affects the expression of LDLRAD3 mRNA23091169
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LDLRAD3 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of LDLRAD3 mRNA26272509
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LDLRAD3 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of LDLRAD3 mRNA22079256
D047428Protein Kinase InhibitorsProtein Kinase Inhibitors inhibits the reaction [gardiquimod results in increased expression of LDLRAD3 mRNA]28003376
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of LDLRAD3 mRNA25895662
D018038Sodium SeleniteSodium Selenite results in increased expression of LDLRAD3 mRNA18175754
D004113Succimer[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of LDLRAD3 mRNA26378955
D013749Tetrachlorodibenzodioxin"[Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in increased expression of LDLRAD3 mRNA"28433925
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LDLRAD3 mRNA25613284
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in decreased expression of LDLRAD3 mRNA28065790
D014212TretinoinTretinoin results in decreased expression of LDLRAD3 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LDLRAD3 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of LDLRAD3 mRNA26272509
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LDLRAD3 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of LDLRAD3 mRNA23179753|2627250

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0001540amyloid-beta binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006898receptor-mediated endocytosis-IEA-  
GO:0070613regulation of protein processing-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-IEA-  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal